3.410SEK-1.39%Mkt Cap: 852.74M SEKP/E: 5.91Last update: 2026-05-13
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind I…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)5.91
P/E (Forward)-3.65
PEG—
P/B3.21
P/S2.69
EV/EBITDA3.62
EV/Revenue1.80
EPS (TTM)0.58
EPS (Forward)-0.94
Cash Flow & Leverage
FCF Yield22.98%
FCF Margin61.88%
Operating CF150.13M SEK
CapEx (TTM)472.00K SEK
Net Debt/EBITDA-1.79
Net Debt-281.82M SEK
Technical
SMA 503.905 (-12.7%)
SMA 2003.782 (-9.8%)
Beta1.65
S&P 52W Chg24.23%
Avg Vol (30d)1.42M
Avg Vol (10d)1.20M
Technical Indicators
RSI (14)33.6
MACD-0.1639
MACD Signal-0.1348
MACD Hist.-0.0291
BB Upper4.221 SEK
BB Middle3.771 SEK
BB Lower3.320 SEK
BB Width23.87%
ATR (14)0.1862 SEK
Vol Ratio (20d)0.44x
52W Range
1.00043% of range6.590
52W High6.590 SEK
52W Low1.000 SEK
Profitability
Gross Margin100.00%
EBITDA Margin49.78%
Profit Margin46.41%
Oper. Margin-391.73%
ROE55.28%
ROA49.54%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity—
Current Ratio9.80
Quick Ratio9.67
Book Value/Sh1.069 SEK
Cash/Share1.134 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.248.61M
Float236.26M
Insiders16.96%
Institutions27.24%
Analyst Consensus
Rating—
Target (Mean)11.25 SEK
Target Range8.500 SEK – 14.00 SEK
# Analysts2
Company
Market Cap852.74M SEK
Enterprise Value570.92M SEK
Revenue (TTM)316.70M SEK
Gross Profit316.70M SEK
Net Income (TTM)146.97M SEK
Revenue/Share1.274 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees22
Last Price3.410 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—